Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Cardiology and Angiology, University Hospital of the Saarland, Kirrbergerstr., 66421 Homburg/Saar, Germany. magnus@baumhaekel.de
The Raynaud's phenomenon often accompanies systemic rheumatic diseases and is also known as a vascular side effect of chemotherapy. Therapy of the Raynaud's phenomenon with nitrates or calcium-channel-blockers is rarely beneficial. In contrast, the PDE-V-inhibitor sildenafil seems to be effective in these patients. For the first time we report on a patient with Raynaud's phenomenon due to chemotherapy not responding to sildenafil but to the new PDE-V-inhibitor tadalafil in an equivalent dosage. Measurement with a laser Doppler revealed an increased blood flow and a reduction of symptoms. Therefore, therapy of Raynaud's phenomenon with the new PDE-V-inhibitor tadalafil seems to be an effective treatment option in patients not responding to sildenafil.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on